

## STATEMENT WITHDRAWN 21<sup>st</sup> February 2025

**This statement has been withdrawn as issues are resolving and supply is beginning to stabilise for the majority of ADHD medicines, with the exception of methylphenidate prolonged-release tablets.**

### Attention Deficit Hyperactivity Disorder (ADHD) Medicines Shortage – Requests for NHS Treatment of New Adult Patients Following Private Diagnosis – Review Version 3

There continues to be intermittent supply issues affecting a range of ADHD medicines, strengths and formulations.

It is essential that the available resources (medication and monitoring) are utilised to manage active patients currently prescribed these medicines, or those NHS patients that have been deferred treatment initiation to date.

Discussions are currently ongoing between Specialist services and Primary Care regarding the NHS Grampian position and treatment pathway for referral, treatment and monitoring of adult patients with ADHD.

Due to these factors NHS Grampian cannot currently support the initiation of treatment for NEW adult patients who have been referred following a Private diagnosis, or continuation of treatment undertaken privately.

Any patient requesting new NHS initiation of ADHD treatments following a Private diagnosis, or continuation of treatment undertaken privately, should be advised that this is not currently possible.

This position will be reviewed either when the treatment pathway has been agreed or by the 1<sup>st</sup> February 2025, whichever is earliest.

Medicines Management Team  
Pharmacy & Medicines Directorate  
Gram.medicinesmanagement@nhs.scot  
1st October 2024